Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Lung Neoplasms 7Neoplasm Metastasis 4Recurrence 3Non Small Cell Lung Cancer Metastatic 3Neuroblastoma 3Neoplasms 3Meningeal Carcinomatosis 2Brain Neoplasms 2Advanced Non-Small Cell Lung Cancer 2ALK Positive Non-small Cell Lung Cancer 2Thrombocytosis 1Sexual Dysfunction, Physiological 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Non-Small Cell Lung Cancer ALK-positive 1Non Small Cell Lung Cancer ALK Positive or ROS1 Positive 1Neurofibromatosis 1 1Neoadjuvant Non-Small Cell Lung Cancer 1NSCLC 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lung Diseases 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Crizotinib 2lorlatinib 1ceritinib 1brigatinib 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ALK-positive NSCLC × lorlatinib × Clear all
NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Pfizer

Completed
549 enrolled 28 charts
Thoracic

ALK-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡